A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
复制标题
对体重减轻的胃肠道癌患者的乙酸酯和布洛芬的前瞻性随机研究。
DOI：
10.1038/sj.bjc.6690077
复制
发表时间：
1999-02
影响因子：
8.8
通讯作者：
McArdle, C S
中科院分区：
文献类型：
--
作者：
McMillan, D C;Wigmore, S J;Fearon, K C;O'Gorman, P;Wright, C E;McArdle, C S
使用醋酸甲地孕酮治疗胃肠道癌症患者的减肥效果令人失望。本研究的目的是比较醋酸甲地孕酮和安慰剂的组合与醋酸甲地孕酮和布洛芬治疗此类患者的减肥效果。在基线、4-6 周和 12 周时，患者使用 EuroQol-EQ-5D 和 EORTC QLQ-C30 进行人体测量、白蛋白和 C 反应蛋白浓度测量，并评估食欲、体能状态和生活质量。 38 名和 35 名患者（中位体重减轻 18%）分别随机接受醋酸甲地孕酮/安慰剂或醋酸甲地孕酮/布洛芬治疗，为期 12 周。四十六 (63%) 患者未能完成为期 12 周的评估。在 12 周时可评估的受试者中，醋酸甲地孕酮/安慰剂组体重下降（中位 2.8 kg），而醋酸甲地孕酮/布洛芬组体重增加（中位 2.3 kg）（P < 0.001）。后者的 EuroQol-EQ-5D 生活质量评分也有所改善（P < 0.05）。醋酸甲地孕酮/布洛芬的组合似乎可以逆转晚期胃肠癌患者的体重减轻并改善生活质量。有必要在患有激素不敏感癌症的减肥患者中进一步试验这种新疗法。 © 1999 癌症研究运动
The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted. © 1999 Cancer Research Campaign